Tissue Repair Ltd (TRP.AX)
AUD 0.27
(0.0%)
AUD 0.27
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 150.51 Thousand AUD | 35066.12% |
| 2023 | 428.00 AUD | -99.75% |
| 2022 | 170.2 Thousand AUD | 11.51% |
| 2021 | 152.63 Thousand AUD | 97743.59% |
| 2020 | 156.00 AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 863.52 Thousand AUD | 0.0% |
| 2024 Q2 | -858.36 Thousand AUD | -3316.78% |
| 2024 Q1 | 26.68 Thousand AUD | 1626.0% |
| 2024 FY | 150.51 Thousand AUD | 35066.12% |
| 2024 Q3 | 863.52 Thousand AUD | 200.6% |
| 2023 Q1 | - AUD | -100.0% |
| 2023 FY | 428.00 AUD | -99.75% |
| 2023 Q4 | 1546.00 AUD | -99.68% |
| 2023 Q3 | 485.82 Thousand AUD | 43555.1% |
| 2023 Q2 | -1118.00 AUD | 0.0% |
| 2022 FY | 170.2 Thousand AUD | 11.51% |
| 2022 Q4 | 84.98 Thousand AUD | -1.13% |
| 2022 Q3 | 85.96 Thousand AUD | 11732.07% |
| 2022 Q2 | -739.00 AUD | 0.0% |
| 2022 Q1 | - AUD | -100.0% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 152.63 Thousand AUD | 97743.59% |
| 2021 Q4 | 76.31 Thousand AUD | 0.0% |
| 2021 Q3 | 76.31 Thousand AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 FY | 156.00 AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 99.705% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 120.097% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -1363.545% |
| Biome Australia Limited | 7.66 Million AUD | 98.038% |
| Patrys Limited | 1.39 Million AUD | 89.204% |
| Orthocell Limited | 3.68 Million AUD | 95.919% |
| Imugene Limited | -5.83 Million AUD | 102.577% |
| Noxopharm Limited | -534.81 Thousand AUD | 128.143% |
| PYC Therapeutics Limited | 22.05 Million AUD | 99.318% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 97.981% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 95.946% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 113.4% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 93.5% |
| CSL Limited | 15.28 Billion AUD | 99.999% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 679.356% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 149.929% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 99.807% |
| Starpharma Holdings Limited | 7.65 Million AUD | 98.034% |
| Nanollose Limited | -348.95 Thousand AUD | 143.132% |
| Memphasys Limited | 1606.00 AUD | -9271.793% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 87.584% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 264.786% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 96.247% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 102.297% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 87.974% |
| Race Oncology Limited | 1.38 Million AUD | 89.171% |
| Nyrada Inc. | -5164.07 AUD | 3014.581% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 99.951% |
| Dimerix Limited | 583.47 Thousand AUD | 74.205% |
| PharmAust Limited | -1641.00 AUD | 9271.907% |
| Immutep Limited | 1.44 Million AUD | 89.576% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 98.692% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 96.044% |
| BTC Health Limited | 16.36 Thousand AUD | -819.994% |
| Acrux Limited | -1.28 Million AUD | 111.722% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 99.927% |
| Biotron Limited | -40.49 Thousand AUD | 471.65% |
| AdAlta Limited | 1.5 Million AUD | 90.019% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 100.706% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | 67.308% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -164.928% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 141.037% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 443.672% |
| Actinogen Medical Limited | 9.93 Million AUD | 98.485% |
| Immuron Limited | 3.33 Million AUD | 95.489% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 94.207% |